AbbVie settles one of its final Humira biosimilar suits for another mid-2023 delayed entry
AbbVie’s blockbuster rheumatoid arthritis drug Humira will see even more competition next year, as AbbVie and biosimilar developer Alvotech settled a court dispute over when the company’s adalimumab biosimilar can launch, even as the drug has yet to be approved by the FDA.
The settlement fully resolves all pending legal US disputes between AbbVie and Alvotech related to the biosimilar, which removes any barriers blocking Alvotech’s high-concentration version of adalimumab from reaching US patients on July 1, 2023.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.